Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer

Area of Science:

• Oncology
• Medical Therapeutics

Background:

• Metastatic breast cancer (MBC) management has seen significant therapeutic advances, improving patient outcomes.
• Current systemic therapies target critical signaling pathways including estrogen receptor, HER2, and PI3K/AKT/mTOR.

Purpose of the Study:

• To review the current state-of-the-art and emerging therapeutic options for managing metastatic breast cancer.
• To discuss novel treatment strategies and future directions in MBC care.

Main Methods:

• Review of current systemic therapy approaches targeting key molecular pathways in MBC.
• Exploration of emerging strategies such as DNA repair inhibition, immune checkpoint inhibition, and antibody-drug conjugates.
• Discussion of evolving roles for locoregional therapy and the impact of technological advancements on treatment paradigms.

Main Results:

• Therapeutic advances targeting estrogen receptor, HER2, and PI3K/AKT/mTOR pathways have improved MBC outcomes.
• Novel strategies including DNA repair targeting, immune checkpoint inhibition, and antibody-drug conjugates represent promising avenues.
• Biomarker-specific, line-agnostic, and receptor-agnostic approaches are poised to redefine MBC treatment paradigms.

Conclusions:

• While not curative, new therapies significantly enhance metastatic breast cancer patient outcomes.
• Future MBC care will be increasingly personalized, driven by biomarkers and advanced technologies.
• Addressing tumor heterogeneity, patient perspectives, treatment costs, and global accessibility is crucial for effective MBC management.